From OncLive, five experts share their perspectives and opinions on the latest research related to triple-negative breast cancer.
Participants include Joyce A. O'Shaughnessy, MD, Baylor-Sammons Cancer Center; Adam M. Brufsky, MD, University of Pittsburg Cancer Institute; Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center; Kevin M. Kalinsky, MD, Columbia University Medical Center; and Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute.
The experts discuss new data from the European Society for Medical Oncology’s (ESMO) Virtual Congress 2020 and standards of care for early-stage triple-negative breast cancer.
“I think that increasingly for our patients with early-stage triple-negative breast cancer, we treat with neoadjuvant chemotherapy. I think that this is for a number of reasons so that we could see how patients are responding to the treatments that we’re giving,” said Dr. Kalinsky.
Visit OncLive to hear their perspectives.
Assessing Onclarity HPV assay safety and efficacy for cervical cancer screening
February 21st 2024A recent study evaluated the safety and effectiveness of the Onclarity HPV assay in detecting high-grade cervical disease, presenting findings on its comparability to predicate assays and potential for cost-saving benefits in screening practices.
Read More
Unifying radical hysterectomy classifications with the Querleu-Morrow
February 16th 2024Explore how the latest research underscores the efficacy of the 2017 Querleu-Morrow classification in defining radical hysterectomy extent, shedding light on surgical terminologies for cervical cancer management.
Read More